secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001104659-23-023529
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q4 2022 revenue $18.8M (+22% YoY); CLEAR Outcomes trial meets MACE-4 endpoint
--------------------------------------------------------------------------------

- CLEAR Outcomes trial met primary MACE-4 endpoint and key secondary endpoints; data to be presented at ACC.23/WCC on March 4, 2023.
- Q4 2022 U.S. net product revenue $15.0M (+23% YoY); full year $55.9M (+40% YoY).
- Net loss Q4 $55.5M ($0.76 per share) vs $65.1M ($1.77) in Q4 2021; full year net loss $233.7M ($3.52) vs $269.1M ($9.31).
- SG&A expenses decreased 37% in Q4 and 41% for full year 2022 vs 2021.
- Entered new $70M ATM sales agreement with Cantor Fitzgerald; terminated prior $250M ATM with Jefferies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/0001104659-23-023529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000110465923023529/tm237313d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-023529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer